Who
David Raben
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Pliant Therapeutics; Chief Medical Officer, Bicara Therapeutics.
In numbers
- Trades disclosed
- 41
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $1.7M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 9 Oct 2025
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Oct 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —575,000 at $0.00 | filing |
| 27 Apr 2026filed 28 Apr 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $21K5,500 at $3.79 | filing |
| 27 Apr 2026filed 28 Apr 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $126K5,500 at $22.88 | filing |
| 27 Apr 2026filed 28 Apr 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,500 at $0.00 | filing |
| 27 Apr 2026filed 28 Apr 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,500 at $0.00 | filing |
| 27 Apr 2026filed 28 Apr 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $21K5,500 at $3.79 | filing |
| 27 Apr 2026filed 28 Apr 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $126K5,500 at $22.88 | filing |
| 25 Mar 2026filed 26 Mar 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $21K5,500 at $3.79 | filing |
| 25 Mar 2026filed 26 Mar 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $104K5,500 at $18.95 | filing |
| 25 Mar 2026filed 26 Mar 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,500 at $0.00 | filing |
| 25 Mar 2026filed 26 Mar 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,500 at $0.00 | filing |
| 25 Mar 2026filed 26 Mar 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $21K5,500 at $3.79 | filing |
| 25 Mar 2026filed 26 Mar 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $104K5,500 at $18.95 | filing |
| 4 Mar 2026filed 5 Mar 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $62K16,300 at $3.79 | filing |
| 4 Mar 2026filed 5 Mar 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,300 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $302K16,300 at $18.52 | filing |
| 4 Mar 2026filed 5 Mar 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,300 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $62K16,300 at $3.79 | filing |
| 4 Mar 2026filed 5 Mar 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $302K16,300 at $18.52 | filing |
| 3 Mar 2026filed 5 Mar 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $758200 at $3.79 | filing |
News
Pliant Therapeutics Names David Raben As CMO To Lead PLN-101095 Developmentrttnews.com · 1 Oct 2026Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officermanilatimes.net · 30 Sep 2026
2 headlines in the last 90 days name David Raben; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.